Skip to main content
Premium Trial:

Request an Annual Quote

DiaGenic Terminates Contract with Investment Firm Terra Markets

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DiaGenic today announced it has terminated its market-making contract with investment firm Terra Markets, effective March 1.

DiaGenic, based in Oslo, Norway, had an agreement with Terra to ensure sufficient trading of its shares, which lists on the Oslo Stock Exchange. But with trading of the company's stock "very high," the molecular diagnostic developer decided that it no longer needed Terra's services, DiaGenic CEO Erik Christensen said in an e-mail.

"The trading in DiaGenic shares is now very high. In fact, it was the sixth-most purchased share in Norway in December," he said. "The cancellation with Terra Markets thus reflects the positive development of DiaGenic."

In October, the company announced that it had raised NOK70 million ($12.1 million) in a private placement, and last month it and Pfizer said they would collaborate on a deal to discover biomarkers for early-stage Alzheimer's disease.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.